New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

In ulcerative colitis (UC), Lilly’s Omvoh has taken ... reduction in BUF among Omvoh-treated patients. Meanwhile, J&J’s Tremfya has secured US approval for UC, but EU approval remains pending ...

Tremfya (guselkumab ... since last September, in ulcerative colitis, achieving sales of almost $3.7 billion last year, but J&J has said that it expects the product to accelerate further now ...

Hunter Renfrow is mounting an NFL comeback after spending the 2024 season out of the league battling ulcerative colitis. Here ...

Renfrow spent the 2024 season dealing with complications from an ulcerative colitis diagnosis. The autoimmune disease left the 29-year-old feeling lethargic as he battled high fevers and ...

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.